Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amifampridine in SMA Type 3
NCT03781479Phase 2Completed
- Start
- Jan 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amifampridine in Spinal muscular atrophy type 3 (SMA3). Started Jan 2019; status: completed.
02
Drugs
amifampridine
03
Conditions
Spinal muscular atrophy type 3 (SMA3)
Beyond the preview
Go deeper on NCT03781479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03781479.